| 1 |
Xu N, Dahlback B. A novel human apolipoprotein (apoM)[J]. J Biol Chem, 1999, 274(44):31286-31290.
|
| 2 |
Luo G, Zhang X, Nilsson-EhleP, et al. Apolipoprotein M[J]. Lipids Health Dis, 2004,3(10):21.
|
| 3 |
Sevvana M, Ahnström J, Egerer-Sieber C, et al. Serendipitous fatty acid binding reveals the structuraldeterminants for ligand recognition in apolipoprotein M[J]. J Mol Biol, 2009,39(4):920-936.
|
| 4 |
Zhang XY, Jiao GQ, Hurtig M, et al. Expression pattern of apolipoprotein M during mouse and humanembryogenesis[J]. Acta Histochem, 2004,106(2):123-128.
|
| 5 |
Luo G, Zhang X, Mu Q, et al. Expression and localization of apolipoprotein M in human colorectal tissues[J]. Lipids Health Dis,2010,9(10):102.
|
| 6 |
Venteclef N. Regulation of anti-atherogenicapolipoprotein M geneexpression by the orphan nuclear receptor LRH-1[J]. Biol Chem,2008,283(7):3694-3701.
|
| 7 |
Huang J, Iqbal J, Saha PK, et al. Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver[J]. Hepatology, 2007,46(1):147-157.
|
| 8 |
Richter S, Shih DQ, Pearson ER, et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha:haploinsufficiency is associated with reduced serum apolipoprotein M levels[J]. Diabetes, 2003,52(12):2989-2995.
|
| 9 |
Wolfrum C, Howell JJ, Ndudgo E, et al. Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M[J]. J Biol Chem, 2008,283(24):16940-16949.
|
| 10 |
Zhao JY, Hu YW, Li SF, et al. Dihydrocapsaicin down-regulates apoM expression through inhibiting Foxa2 expression and enhancing LXRα expression in HepG2 cells[J]. Lipids Health Dis, 2014,19(10):1186-1193.
|
| 11 |
Zhang, X, Zhu Z, Luo G, et al. Liver X receptor agonist downregulates hepatic apoM expression in vivo and in vitro[J]. Biochem Biophys Res Commun, 2008,371(1):114-117.
|
| 12 |
Zhu C, Di D, Zhang X, et al. TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells[J]. Lipids Health Dis, 2011,199(10):1476-1479.
|
| 13 |
Calayir E, Becker TM, Kratzer A, et al. LXR-agonists regulate apoM expression differentially in liver and intestine[J]. Curr Pharm Biotech,2008,9(6):516-521.
|
| 14 |
Xu N, Hurtig M, Zhang XY, et al. Transforming growth factor-beta down-regulates apolipoprotein M in HepG2 cells[J]. Biochim Biophys Acta, 2004,1683(1-3):33-37.
|
| 15 |
Feingold KR, Shigenaga JK, Chui LG, et al. Infection and inflammation decrease apolipoprotein M expression[J].Atherosclerosis, 2008,199(1):19-26.
|
| 16 |
Hu YW, Zheng L, Wang Q, et al. Vascular endothelial growth factor downregulates apolipoprotein M expression by inhibiting Foxa2 in a Nur77-dependent manner[J]. Rejuvenation Res, 2012,15(4):423-434.
|
| 17 |
Xu N, Nilsson-Ehle P, Ahren B. Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects [J]. J Nutr Biochem, 2004,15(10):579-582.
|
| 18 |
Luo G, Hurtig M, Zhang X, et al. Leptin inhibits apolipo-protein M transcription and secretion in human hepatomacell line, HepG2 cells[J]. Biochim Biophys Acta, 2005,1734(2):198-202.
|
| 19 |
Xu N, Ahren B, Jiang J, et al. Down-regulation of apolipoprotein M expression is mediated by phosphatidylinositol 3-kinase in HepG2 cells[J]. Biochim Biophys Acta, 2006,1761(2):256-260.
|
| 20 |
Zhang X, Jiang B, Luo G, et al. Hyperglycemia down-regulates apolipoprotein M expression in vivo and in vitro[J]. Biochimicaet Biophysica Acta, 2007,1771(7):879-882.
|
| 21 |
Cervin C, Axler O, Holmkvist J, et al. An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA[J]. J Intem Med, 2010,267(3):316-321.
|
| 22 |
Zhou JW, Tsui SK, Ng MC, et al. Apolipoprotein M gene (APOM)polymorphism modifies metabolic and disease traits in type 2 diabetes[J]. PLoS One, 2011,6(2):e17324.
|
| 23 |
Mughal SA, Park R, Nowak N, et al. Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes[J]. Diabet Med,2013,30(2):246-250.
|
| 24 |
Kurano M, Hara M, Tsuneyama K, et al. Induction of insulin secretion by apolipoprotein M, a carrier for sphingosine 1-phosphate[J].Biochim Biophys Acta, 2014,5(14):1388-1398.
|
| 25 |
Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis[J]. Nat Med, 2005,11(4):418-422.
|
| 26 |
Christoffersen C, Jauhiainen M, Moser M，et al. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice[J].Biol Chem, 2008,283(4):1839-1847.
|
| 27 |
胡志高, 屈晓冰, 胡敏. 载脂蛋白M 与冠状动脉病变的关系[J]. 中国动脉硬化杂志, 2008,16(3):224-226.
|
| 28 |
Mulya A, Seo J, Amanda L, et al. Apolipoprotein M expression increases the size of nascent preβ HDL formed by ATP binding cassette transporter A1[J]. Lipid Res, 2010,51(3):514-524.
|
| 29 |
Liu M, Seo J, Allegood J, et al. Hepatic apolipoprotein M (apoM)overexpression stimulates formation of larger apoM/sphingosine 1-phosphate-enriched plasma high density lipoprotein[J]. J Biol Chem,2014,289(5):2801-2814.
|
| 30 |
Christoffersen C, Obinata H, Kumaraswamy SB, et al. Endotheliumprotective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M[J]. Proc Natl Acad Sci U S A, 2011,108(23):9613-9618.
|
| 31 |
Xu WW, Zhang Y, Tang YB, et al. A genetic variant of apolipoprotein M increases susceptibility to coronary artery disease in a Chinese population[J]. Clin Exp Pharmacol Physiol, 2008,35(5-6):546-551.
|
| 32 |
Zheng L, Luo G, Zhang X, et al. Determination of single-nucleotide polymorphism in the proximal promoter region of apolipoprotein M gene in coronary artery diseases[J]. Int G Med, 2009,29(2):177-182.
|
| 33 |
Zhang Z, Chu G, Yin RX, et al. Apolipoprotein M T-778C polymorphism is associated with serum lipid levels and the risk of coronary artery disease in the Chinese population: a meta-analysis[J].Lipids Health Dis, 2013,12(10):135-144.
|
| 34 |
Zheng L, Luo G, Zhang J, et al. Decreased activities of apolipoprotein m promoter are associated with the susceptibility to coronary artery diseases[J]. Int J Med Sci, 2014,11(4):365-372.
|
| 35 |
郑璐, 张俊, 牟琴峰, 等. 载脂蛋白M 启动子区的一个新单核苷酸多态性位点及其与冠心病易感性的关系[J]. 中华心血管病杂志,2014,42(4):284-289.
|